Long-term results of growth hormone therapy in Turner syndrome.
Short stature is one of the main features of Turner syndrome. Today, most patients are treated with growth hormone (GH) to improve adult height. We have reviewed the literature reporting adult height in patients with Turner syndrome treated with GH alone or in combination with oxandrolone. The reported adult heights as well as the height gain over projected or predicted height are still preliminary and vary considerably among studies. There is some evidence that the age of onset of therapy, dose of GH, duration of GH therapy, target height, time of estrogen substitution, or concurrent treatment with oxandrolone affect adult height. The reported height gains over projected height range from -0.20 to +16.0 cm (median: 5.1 cm) in patients treated with GH and from +0.68 cm to +10.3 (median: 6.40 cm) in patients treated with GH and oxandrolone. Thus, the presently available data are extremely varied and need further detailed analysis after all ongoing clinical trials have published the final results of all patients included in the study.
Bramswig
J H
JH
University Children's Hospital, Department of Pediatrics, Münster, Germany. bramswi@uni-muenster.de
D000293:Adolescent; D001827:Body Height; D002648:Child; D004967:Estrogens / Q000008:administration & dosage; D005260:Female; D019382:Human Growth Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D010074:Oxandrolone / Q000008:administration & dosage / Q000627:therapeutic use; D014424:Turner Syndrome / Q000188:drug therapy*
D004967:Estrogens; D019382:Human Growth Hormone; D010074:Oxandrolone